Inovio reports first quarter 2025 financial results and recent business highlights

On track to begin rolling submission of biologics license application (bla) for ino-3107 as a potential treatment for recurrent respiratory papillomatosis (rrp) in mid-2025 device design verification (dv) testing of cellectra device required for bla submission is underway, anticipated completion in 1h25 clinical and immunological results from phase 1/2 trial of ino-3107 published in nature communications in february 2025 ino-3107 induced new populations of t cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery announced promising interim results from ongoing proof-of-concept phase 1 trial showing dna-encoded monoclonal antibodies (dmabs) were well tolerated and exhibited long-lasting in vivo production preprint manuscript available on researchsquare.com  plymouth meeting, pa. , may 13, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments.
INO Ratings Summary
INO Quant Ranking